TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38869653

Group type: EXPERIMENTAL
Intervention: Disclosure as a stigma management strategy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Non-disclosure strategies
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Experiences of psychosis stigma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Understanding from others
Number of subjects: 34
Study: 38869683

Group type: EXPERIMENTAL
Intervention: Hospital-based training group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Home-based training group
Number of subjects: 24
Study: 38869701

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.025 µg/kg/min
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.05 µg/kg/min
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.075 µg/kg/min
Number of subjects: 180

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 180
Study: 38869746

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg orally BID plus celecoxib 200 mg orally once daily for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo tablets BID plus celecoxib 200 mg orally once daily for 12 weeks
Number of subjects: 50
Study: 38869771

Group type: EXPERIMENTAL
Intervention: Talazoparib monotherapy
Number of subjects: 61
Study: 38869780

Group type: EXPERIMENTAL
Intervention: Newly developed improved radio-TLC method
Number of subjects: 0
Study: 38869865

Group type: COMPARATOR
Intervention: Cessation of TKI treatment and follow-up every 3 months.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retreatment due to detectable ctDNA and/or elevated CEA levels.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Retreatment due to progressive disease.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall response rate to TKI retreatment.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Time to next treatment.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall survival data.
Number of subjects: 60
Study: 38869899

Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy (EAET)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 126
Study: 38869902

Group type: EXPERIMENTAL
Intervention: Hand scan image group
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Instructional video group
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Hand scan image with instructional video group
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study: 38869930

Group type: EXPERIMENTAL
Intervention: PRIOR (Protocol for Increasing Data Integrity in Online Research)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Initial protocol for preventing fraudulent participation
Number of subjects: 1300
Study: 38869931

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusions initiated at hemoglobin level ≤10 g/dL)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusions initiated at hemoglobin level ≤7 g/dL)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 742

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 742
Study: 38869943

Group type: EXPERIMENTAL
Intervention: Tailored eHealth self-management intervention based on the Dutch Medical Dashboard (MD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally tailored, standardized eHealth self-management intervention
Number of subjects: 0
Study: 38869947

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 50
Study: 38869978

Group type: EXPERIMENTAL
Intervention: Antidepressants (specific mention of paroxetine and sertraline)
Number of subjects: 4575

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 4575

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 4575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4575
Study: 38869987

Group type: EXPERIMENTAL
Intervention: Avenciguat 1 mg twice-daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Avenciguat 2 mg twice-daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Avenciguat 3 mg twice-daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 38870076

Group type: EXPERIMENTAL
Intervention: Wearable monitoring device based on an Internet management platform
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional diabetes treatments
Number of subjects: 120
Study: 38870103

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard therapy (Norepinephrine)
Number of subjects: 45
Study: 38870156

Group type: EXPERIMENTAL
Intervention: MediYoga
Number of subjects: 46

Group type: COMPARATOR
Intervention: Physiotherapy treatment as usual
Number of subjects: 46
Study: 38870517

Group type: EXPERIMENTAL
Intervention: Functional Pain Scale (FPS)
Number of subjects: 232
Study: 38870573

Group type: EXPERIMENTAL
Intervention: Self-reported exhaustion (SRE)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: 4-item Physical Frailty Index (4i-PFI)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Timed Up-and-Go (TUG)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Handgrip Strength (HGS)
Number of subjects: 493
Study: 38870745

Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 1
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 2
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 3
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 4
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAEs)
Number of subjects: 72
Study: 38870749

Group type: EXPERIMENTAL
Intervention: Qilong capsule (QLC) combined with conventional treatment (CT)
Number of subjects: 2302

Group type: COMPARATOR
Intervention: Conventional treatment (CT) alone
Number of subjects: 2302
Study: 38870931

Group type: EXPERIMENTAL
Intervention: Serplulimab (300 mg) plus HLX04 (7.5 mg/kg) and XELOX
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (300 mg) plus bevacizumab (7.5 mg/kg) and XELOX
Number of subjects: 114
Study: 38870977

Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan (70 mg/m²) plus fluorouracil plus leucovorin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluorouracil plus leucovorin
Number of subjects: 100
Study: 38870979

Group type: EXPERIMENTAL
Intervention: Garsorasib (D-1553), open-label, single-arm, phase 2 trial
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Garsorasib (D-1553)
Number of subjects: 123
Study: 38871018

Group type: EXPERIMENTAL
Intervention: Binge drinkers (BDs)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non/low-drinkers (N/LDS)
Number of subjects: 82
Study: 38871148

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Repeated FMT treatments
Number of subjects: 467
Study: 38871269

Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred group (control)
Number of subjects: 0
Study: 38871445

Group type: EXPERIMENTAL
Intervention: IQOS 3.0
Number of subjects: 90
Study: 38871454

Group type: EXPERIMENTAL
Intervention: Community-based STI screening for youth
Number of subjects: 5601
Study: 38871487

Group type: EXPERIMENTAL
Intervention: CG-806
Number of subjects: 0
Study: 38871558

Group type: EXPERIMENTAL
Intervention: Talquetamab (bispecific antibody targeting GPRC5D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talquetamab
Number of subjects: 0
Study: 38871565

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) integrated with clinical score and d-dimer testing
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Age-adjusted d-dimer
Number of subjects: 1979
Study: 38871657

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.02 mg/kg intravenous infusion over 4 hours prior to organ retrieval
Number of subjects: 414

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 414
Study: 38871679

Group type: COMPARATOR
Intervention: 10% metronidazole
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 10% metronidazole + 2% diltiazem
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 10% metronidazole + 4% lidocaine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 10% metronidazole + 2% diltiazem + 4% lidocaine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 192
Study: 38871702

Group type: EXPERIMENTAL
Intervention: Error-corrected-NGS-MRD
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: WT1-MRD
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: NPM1 mutation detection
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: NGS-MRD
Number of subjects: 189
Study: 38871705

Group type: EXPERIMENTAL
Intervention: palbociclib, fulvestrant, trastuzumab, and pyrotinib
Number of subjects: 15
Study: 38871715

Group type: EXPERIMENTAL
Intervention: Community gardening intervention
Number of subjects: 291
Study: 38871878

Group type: EXPERIMENTAL
Intervention: Performance-based reimbursement model (PBRM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-rate model (FRM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Up-front allocation model (UFAM)
Number of subjects: 0
Study: 38871947

Group type: EXPERIMENTAL
Intervention: DAPT > 12 months
Number of subjects: 1000

Group type: COMPARATOR
Intervention: DAPT ≤ 12 months
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: DAPT > 12 months (HIR)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: DAPT > 12 months (Technical HIR)
Number of subjects: 1000
Study: 38871975

Group type: EXPERIMENTAL
Intervention: Botensilimab (BOT) plus balstilimab (BAL)
Number of subjects: 148
Study: 38872109

Group type: EXPERIMENTAL
Intervention: BCI-FES paired with PT
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dose-matched PT sessions
Number of subjects: 66
Study: 38872174

Group type: EXPERIMENTAL
Intervention: Transrectal biopsy (TRUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anaesthetic transperineal biopsy (LATP)
Number of subjects: 0
Study: 38872173

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) with low carbohydrate, high protein calorie-restricted diet (CRD), exercise, and intensive counseling from a dietitian
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group with balanced calorie-restricted diet (CRD), exercise, and standard counseling
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study: 38872193

Group type: EXPERIMENTAL
Intervention: Diet + Supplementation: individualized diet supplemented with 604 mg of omega-3 fatty acids, three times a day
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diet + Placebo: individualized diet + 1 g of soybean oil
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo: 1 g of soybean oil daily, no dietetic intervention
Number of subjects: 91
Study: 38872204

Group type: EXPERIMENTAL
Intervention: High-intensity intervention group (personalized, supervised, hybrid intervention with group meetings and individual sessions)
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Low-intensity intervention group (bi-monthly online lifestyle-related health advice)
Number of subjects: 1210
Study: 38872214

Group type: EXPERIMENTAL
Intervention: 15-method intervention in primary care
Number of subjects: 0
Study: 38872480

Group type: EXPERIMENTAL
Intervention: Bevacizumab + carboplatin and paclitaxel (CP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo + carboplatin and paclitaxel (CP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bevacizumab + CP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo + CP
Number of subjects: 100
Study: 38872812

Group type: EXPERIMENTAL
Intervention: Reality Digital Therapeutics (Reality DTx) - 6-week AR exergaming intervention, default five sessions/week of 30 active minutes/session
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 24
Study: 38872829

Group type: EXPERIMENTAL
Intervention: 40 Hz VTS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 100 Hz VTS
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: VTS (both dosages)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: VTS (not receiving Botulinum treatment)
Number of subjects: 39
Study: 38872830

Group type: EXPERIMENTAL
Intervention: HLA/MAGE-A4 assays validation for TCR T cell therapies
Number of subjects: 6606

Group type: EXPERIMENTAL
Intervention: MAGE-A4 prevalence in clinical trial enrollment
Number of subjects: 6606

Group type: EXPERIMENTAL
Intervention: MAGE-A4 prevalence by tumor type
Number of subjects: 6606

Group type: EXPERIMENTAL
Intervention: Covariates analysis
Number of subjects: 6606
Study: 38872994

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 38873124

Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab-cilgavimab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Authentic- and lentiviral pseudovirus-based neutralisation assays
Number of subjects: 0
Study: 38873183

Group type: EXPERIMENTAL
Intervention: Disposable e-cigarettes for 8 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 120
Study: 38873265

Group type: EXPERIMENTAL
Intervention: Rest myocardial blood flow (MBF)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Myocardial work efficiency (MWE)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) systolic dysfunction
Number of subjects: 92
Study: 38873632

Group type: EXPERIMENTAL
Intervention: Upadacitinib 6 mg (UPA6)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Upadacitinib 11 mg (UPA11)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Upadacitinib 22 mg (UPA22)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 185
Study: 38873634

Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin (OXY) - 10UI intramuscularly within 5 minutes from childbirth
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TRAN) - 1-g slow intravenous infusion within 5 minutes from childbirth
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 256
Study: 38873657

Group type: EXPERIMENTAL
Intervention: Brief quitline intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 38873723

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) plus standard care
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control (standard care alone)
Number of subjects: 507
Study: 38873885

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin (500 mg)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2013
Study: 38873891

Group type: EXPERIMENTAL
Intervention: Teduglutide
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (no teduglutide)
Number of subjects: 85
Study: 38873934

Group type: EXPERIMENTAL
Intervention: vemurafenib at 550 mg/m2 (maximum 960 mg/dose) orally twice daily for 28-day cycles
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: vemurafenib
Number of subjects: 4
Study: 38874333

Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of Ipilimumab and Nivolumab (IPI + NIVO)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (Standard treatment)
Number of subjects: 32
Study: 38874488

Group type: EXPERIMENTAL
Intervention: Sufficiently active physical activity (≥600 MET-min/week) and qualified dietary quality (≥60)
Number of subjects: 3007

Group type: EXPERIMENTAL
Intervention: Insufficiently active physical activity (>0 MET-min/week) and qualified dietary quality (≥60)
Number of subjects: 3007
Study: 38874505

Group type: EXPERIMENTAL
Intervention: Bankart repair with remplissage (REMP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Isolated Bankart repair (NO REMP)
Number of subjects: 108
Study: 38874529

Group type: EXPERIMENTAL
Intervention: MAP MRI metrics
Number of subjects: 271

Group type: COMPARATOR
Intervention: ADC
Number of subjects: 271
Study: 38874618

Group type: EXPERIMENTAL
Intervention: GLP-1RA
Number of subjects: 92

Group type: COMPARATOR
Intervention: SGLT2 inhibitor
Number of subjects: 92

Group type: COMPARATOR
Intervention: Neither therapy
Number of subjects: 92
Study: 38874697

Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Number of subjects: 97

Group type: COMPARATOR
Intervention: Ferric carboxymaltose
Number of subjects: 97
Study: 38874739

Group type: EXPERIMENTAL
Intervention: CTC 200 mg BID
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Tramadol 50 or 100 mg four times a day
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Celecoxib 100 mg BID
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039
Study: 38874763

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unstructured social interviewing (placebo)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 38874776

Group type: EXPERIMENTAL
Intervention: dPTFE group (tooth extraction and alveolar ridge preservation using intentionally exposed dPTFE membrane)
Number of subjects: 44

Group type: COMPARATOR
Intervention: USH group (tooth extraction and unassisted socket healing)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: dPTFE group
Number of subjects: 44
Study: 38875108

Group type: EXPERIMENTAL
Intervention: Repotrectinib (Augtyro)
Number of subjects: 127
Study: 38875119

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA) plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo plus GemCis (gemcitabine 1000 mg/m2 + cisplatin 25 mg/m2 on days 1 and 8 every 3 weeks for 8 cycles)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA) plus GemCis
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo plus GemCis
Number of subjects: 297
Study: 38875120

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) of the motor cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New algorithm for predicting response to rTMS
Number of subjects: 0
Study: 38875121

Group type: EXPERIMENTAL
Intervention: Long-acting dexamethasone viscous gel delivered by transforaminal injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38875111

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole (40 mg daily)
Number of subjects: 4821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4821
Study: 38875279

Group type: EXPERIMENTAL
Intervention: LUNA treatment delivered twice weekly for 10 weeks via videoconferencing (Zoom)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LUNA treatment
Number of subjects: 28
Study: 38875292

Group type: EXPERIMENTAL
Intervention: SMS program (health education program delivered via SMS)
Number of subjects: 7890

Group type: COMPARATOR
Intervention: Non-SMS group (control)
Number of subjects: 7890
Study: 38875501

Group type: EXPERIMENTAL
Intervention: German ED Senior AID tool
Number of subjects: 1010

Group type: COMPARATOR
Intervention: All patients
Number of subjects: 1010
Study: 38875516

Group type: EXPERIMENTAL
Intervention: Comprehensive Stroke Center (CSC)
Number of subjects: 1961

Group type: EXPERIMENTAL
Intervention: Transfer from TSC/PSC to CSC
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Telestroke Center (TSC) / Primary Stroke Center (PSC)
Number of subjects: 1961
Study: 38875550

Group type: EXPERIMENTAL
Intervention: AI-enabled screening tool
Number of subjects: 29
Study: 38875564

Group type: EXPERIMENTAL
Intervention: App feature use patterns
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Logistic regression model including SML-predicted probabilities
Number of subjects: 133
Study: 38875579

Group type: EXPERIMENTAL
Intervention: Personalized automatic messaging system (PAMS) using SMS text messaging and data integration into clinical workflows
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) models using weekly and daily DPP data sets (328,821 and 704,242 records)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement with any activity in the dDPP in the last 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latent profile analysis after 2 weeks of engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning methods for tailoring messaging interventions
Number of subjects: 0
Study: 38875682

Group type: EXPERIMENTAL
Intervention: Cinematographic recordings during maximum flexion and extension
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cinematographic recordings during maximum extension
Number of subjects: 11
Study: 38875880

Group type: EXPERIMENTAL
Intervention: Office-based addiction treatment (OBAT)
Number of subjects: 1988

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1988
Study: 38876123

Group type: EXPERIMENTAL
Intervention: AI system
Number of subjects: 9129

Group type: COMPARATOR
Intervention: Radiologists using PI-RADS (2.1)
Number of subjects: 9129
Study: 38876129

Group type: EXPERIMENTAL
Intervention: Sustained lupus low disease activity state (LLDAS)
Number of subjects: 3449

Group type: EXPERIMENTAL
Intervention: Remission
Number of subjects: 3449
Study: 38876132

Group type: EXPERIMENTAL
Intervention: 16-Gy stereotactic radiotherapy (SRT)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Sham SRT
Number of subjects: 411
Study: 38876137

Group type: EXPERIMENTAL
Intervention: Hypothermia (34-35°C)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Normothermia (36·5-37·5°C)
Number of subjects: 365
Study: 38876630

Group type: EXPERIMENTAL
Intervention: Mulligan mobilization technique plus conventional physiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40